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ScienceDirectReprogramming has the potential to provide specific cell types
for regenerative medicine applications aiming at replacing
tissues that have been lost or damaged due to degenerative
diseases and injury. In this review we discuss the latest
strategies and advances of in vivo reprogramming to convert
cell identities in living organisms, including reprogramming
induced by transcription factors (TFs) and CRISPR/dCas9
synthetic TFs, as well as by cell fusion and small molecules. We
also provide a brief recap of reprogramming barriers, the effect
of senescence on reprogramming efficiency, and strategies to
deliver reprogramming factors in vivo. Because of the limited
space, we omit dwelling on naturally occurring reprogramming
phenomena such as developmentally programmed
transdifferentiation found in the nematode Caenorhabditis
elegans.
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Introduction
The dogma that differentiated cells have restricted cel-
lular plasticity was already challenged in 1958 by John
Gurdon, who cloned the frog Xenopus laevis using nuclear
transfer [1]. This pioneering work inspired Campbell et al.
to clone the sheep Dolly 40 years later [2]. In the
meantime, in 1987, Davis et al. directly reprogrammed
mouse fibroblasts into muscle cells, in a process also
known as transdifferentiation, by ectopic overexpression
of the transcription factor (TF) MyoD, while Gehring’s
team transdifferentiated Drosophila antenna into legs
using ectopic overexpression of the TF Antennapedia
[3,4]. The emergence of a broader reprogramming
research field started 2006, when Takahashi andwww.sciencedirect.com Yamanaka published that the TF cocktail Oct3/4,
Sox2, Klf4 and c-Myc (aka OSKM) reprograms somatic
cells to a state of pluripotency, thereby generating
‘induced pluripotent stem cells’ (iPSCs) [5]. Commonly,
most reprogramming procedures are performed in vitro,
but the much-anticipated scenario of utilizing reprogram-
ming for regenerative medicine applications raises the
need for in vivo reprogramming.
From in vitro to in vivo reprogramming
Decades of developmental biology research in various
model organisms identified cell fate-inducing TFs that
can be used for cellular reprogramming. Forced expres-
sion of one single TF such as MyoD (induces muscle fate)
[3], or C/EBPa (induces B-cell conversion to macro-
phages [6], and in Caenorhabditis elegans the Zn-finger
TF CHE-1 (germ cell reprogramming to neurons)
[7,8], or the GATA TF ELT-7 (induces intestinal fate)
[9], can be sufficient to induce cell fate conversion. Other
types of reprogramming require combination of different
TFs: OSKM reprogram differentiated cells to iPSCs [5],
Ascl1 +Brn2 +Myt1L transdifferentiate fibroblasts to
neurons [10], and Ngn3 +Pdx1 +Mafa directly convert
pancreatic cells to insulin-producing b-cells [11]. Initially,
TF-induced cellular conversion in vivo could be demon-
strated mainly in Drosophila [4] and C. elegans [8]. In
contrast, most mammalian reprogramming procedures
were performed in vitro, except the in vivo transdiffer-
entiation of pancreatic cells to b-cells in insulin-deficient
mice by viral delivery of TFs to the pancreas [11].
Subsequently, iPSC reprogramming was achieved in vivo
by two independent groups using transgenic mice with
doxycycline-inducible OSKM [12,13], and differentiated
cells of murine retinas could be reprogrammed to a
progenitor-like state via cell fusion [14]. While such
reprogramming experiments raised the hope for generat-
ing tissues by in vivo reprogramming, safety concerns and
the issue of limited conversion efficiency remain. In vivo
cell fate conversion requires high efficiency in order to
generate sufficient target cells, while preventing the
generation of cell populations, which could give rise to
tumours.
Current in vivo reprogramming strategies are summarized
in Figure 1.
Efficiency of in vivo reprogramming
Differences between in vitro and in vivo reprogramming
efficiencies could arise from local microenvironmental
conditions. Notably, the gene expression profile of
in vivo generated iPSCs is more similar to that of embry-
onic stem cells (ESCs), as in vitro generated ones [12].Current Opinion in Cell Biology 2019, 61:9–15
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Overview of current reprogramming strategies. Somatic cells can be directly reprogrammed in vivo by using one or several of the following
methods: Removing reprogramming barriers, cell fusion, natural lineage-promoting TFs, synthetic CRISPR/dCas9 TFs, small molecules (‘chemical
reprogramming’) and modulating the microenvironment.Furthermore, in vivo-generated iPSCs harbour character-
istics of totipotency as they can differentiate to trophec-
toderm – a feature that ESCs generally do not possess
[12]. Interestingly, reprogramming efficiency could also
be linked to senescence – a protective cellular mecha-
nism, which increases with aging and upon tissue damage.
In fact, OSKM overexpression in vivo induces tissue
damage and many cells respond to this insult by becom-
ing senescent [15]. While senescence has been described
as a reprogramming barrier in vitro [16], it appears that
senescent cells promote in vivo reprogramming in their
direct vicinity through the secretion of various soluble
factors, also known as senescence-associated secretory
phenotype (SASP) [15,17]. Generally, SASP reinforces
senescence, recruits immune cells, promotes tissue remo-
delling, and also stimulates regeneration and cellular
plasticity: oncogenic-induced senescence in the liver
reactivates stem cell markers in non-senescent cells
[17] and injury-induced senescence enables reprogram-
ming of Pax7+ muscle stem cells [18]. Likewise, Nanog-
positive stem cells in murine lungs could only be gener-
ated by in vivo reprogramming upon treatment with the
DNA damaging agent Bleomycin to trigger senescence
[15]. Analogously to injury-triggered senescence, age-
related senescence also promotes reprogramming, how-
ever, with increased teratoma formation as a by-product.
It is conceivable that, besides increased senescence, also
cell-autonomous fate protection mechanisms mightCurrent Opinion in Cell Biology 2019, 61:9–15 decrease during aging [11,14]. Among SASP, interleukin
6 (IL6) seems to play a crucial role for the increased
efficiency of in vivo reprogramming [15,18]. Many senes-
cence-related signalling pathways are regulated by the
INK4a/ARF locus, which acts as a reprogramming barrier
in vitro [16,19], but promotes reprogramming in vivo [15].
In the absence of INKa/ARF, tissues fail to efficiently
secrete cytokines, including IL6, resulting in reduced in
vivo reprogramming [15]. In this context, a recent study
showed that INK4a is required for OSKM-mediated
senescence, while ARF is dispensable [20]. Such striking
differences of in vivo versus in vitro reprogramming with
respect to signalling pathways emphasize the importance
of using in vivo models to study reprogramming. Since
many degenerative diseases such as Alzheimer’s or Mus-
cular Dystrophy are age-related, the fact that cells in an
aged organism might be easier to reprogram, is encourag-
ing. However, the accompanying formation of teratomas
prompts for measures to prevent detrimental side-effects
during in vivo reprogramming.
Recent in vivo reprogramming examples
Reprogramming to liver cells
The liver is one of the few mammalian organs that has a
natural regenerative capacity and is endogenously
repaired after injury. The regenerative capacity of the
liver seems to be dependent on bone marrow cell (BMC)
migration and their fusion with hepatocytes [21]. Thiswww.sciencedirect.com
In vivo reprogramming Ofenbauer and Tursun 11fusion forms hybrid cells that proliferate and produce
cells for liver regeneration [21]. Furthermore, ectopic
expression of the TFs FOXA3, GATA4, HNF1A, and
HNF4A from a lentiviral vector can convert murine
myofibroblasts into hepatocyte-like cells in vivo (repro-
grammed hepatocytes, rHeps) [22]. Recently Cheng et al.
demonstrated that injection of FOXA3, HNF1A, and
HNF4A into patient-derived tumour xenografts repro-
grammed carcinoma cells into rHeps in living mice, which
lost malignant phenotypes and retrieved hepatocyte-spe-
cific characteristics [23]. This intriguing example demon-
strates that in vivo reprogramming could also serve as a
therapeutic strategy for cancer treatment.
Direct conversion to neuronal cells
Another recent study showed that BMCs can fuse with
neuronal cells in murine adult brains, which might be a
mechanism to protect and regenerate brain tissues. As cell
fusion can induce cellular reprogramming by altering
cellular plasticity [24], BMCs are in the focus of many
studies aiming to achieve reprogramming of different
tissues in vivo. For instance, it was shown that trans-
planted BMCs into a humanized mouse model of
Friedreich’s ataxia could stimulate neuronal repair in
the brain [25]. Furthermore, it was found that following
retinal damage, endogenous BMCs migrated to the injury
site and fused with Mu¨ller glia cells (MGCs), which then
converted into retinal neurons [26]. This endogenous
repair process could be enhanced by perturbations of the
SDF1/CXCR4 pathway, which led to higher in vivo
reprogramming efficiencies of MGCs to neurons [26].
Importantly, MGCs of new-born mice can also be con-
verted to neurons by ectopic expression of the TF Ascl1
[27]. However, MGCs derived after postnatal day
16 required the addition of the histone deacetylase inhib-
itor trichostatin-A, indicating a more repressive chromatin
state of older MGCs. Indeed, the overall chromatin state
of younger MGCs appeared to be in a more permissive
state as measured by an assay for transposase-accessible
chromatin (ATAC-seq), thus highlighting the importance
of removing epigenetic reprogramming barriers in order
to increase reprogramming efficiency in vivo [27]. Strik-
ingly, based on these findings, Yao et al. succeeded in
partially restoring vision in congenitally blind mice [28].
They first stimulated proliferation of MGCs with b-cate-
nin and subsequently induced reprogramming by over-
expressing the rod cell fate-specifying TFs Otx2, Crx,
and Nrl. Four weeks later, the primary visual cortex of
treated mice showed activity after light exposure, indi-
cating that generated rod cells were functional and inte-
grated into already existing retinal circuits [28].
Further, a recent study demonstrates neuronal in vivo
conversion of neuroblasts into mature myelinating oligo-
dendrocytes by forced expression of the TFs OLIG2 and
SOX10 in a demyelination mouse model. Interestingly,www.sciencedirect.com this reprogramming occurred also spontaneously with
very low frequency in the absence of ectopic TF expres-
sion, revealing an unexpected plasticity of committed
neuroblasts [29]. More recently, Matsuda et al. reported
that the TF NeuroD1, which had previously been shown
to directly reprogram astrocytes in the cortex of stab-
injured mice into neurons [30], is able to transdifferenti-
ate microglia to neurons in vitro and in vivo [31]. This
potential of NeuroD1 relies on its ability to occupy
bivalent chromatin domains to initiate neuronal gene
expression, before suppressing microglial genes by alter-
ing the epigenome [31]. Generally, the recent success in
neuronal in vivo reprogramming could be a future strategy
to treat lesions in the adult brain.
Generation of muscle and other cell types by
reprogramming
The earlier mentioned senescence-dependent in vivo
reprogramming of Pax7+ muscle stem cells [18] is only
one of several recent in vivo muscle reprogramming
examples. For instance, cardiomyocytes could be gener-
ated from cardiac fibroblasts by ectopically overexpres-
sing the TFs Gata4, Mef2c, and Tbx5 [32,33], or by
small-molecule compounds [34]. Furthermore, transient
reprogramming by OKSM factors in skeletal muscle
enhances regeneration without tumorigenic side effects
[35], which also improves multiple aging symptoms by
inducing rejuvenation as seen in a mouse model of
progeria [36].
Another recent study by Kurita et al. reports the in vivo
reprogramming of wound-resident mesenchymal cells to
epithelial cells. Viral delivery of the factors DNP63A,
GRHL2, TFAP2A, and MYC leads to epithelialization
from the surface of cutaneous ulcers in mice [37]. Such in
vivo reprogramming could be used to cure non-healing
wounds, further highlighting the potential of cellular
reprogramming for regenerative medicine.
Delivery of reprogramming factors in vivo
The use of genome integrating viruses for the delivery of
reprogramming factors bears risks such as insertional
mutagenesis, which prompt for alternative methods bet-
ter suited for future clinical applications: non-integrative
Sendai virus vectors were applied to deliver cardiac
reprogramming factors in vivo to reduce fibrosis in a
mouse model of myocardial infarction [32]. Also, nano-
particle-based gene carriers were used to convert fibro-
blasts into cardiomyocytes in vivo [33], or a tissue nano-
transfection device generating a focused electric field for
direct cytosolic delivery of DNA in vivo to transdiffer-
entiate fibroblasts into endothelial cells [38].
An alternative approach to using reprogramming TFs is
the application of small molecules, which has recently
been reviewed [39]. For instance, a chemical cocktail
could directly reprogram adult cardiac fibroblasts intoCurrent Opinion in Cell Biology 2019, 61:9–15
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Table 1
Recent studies reporting in vivo reprogramming
Starting cell fate Target cell fate Reprogramming factors/
reagent
Delivery/induction Species+context Reference
Undefined Teratoma OCT4, SOX2, KLF4, cMYC Inducible transgenic DNA Mouse+ senescence ind. Mosteiro et al. [15]
Epithelial/liver cell Stem cell-like H-RasV12-induced
senescence
Transposable DNA injection Mouse+ senescence ind. Ritschka et al. [17]
Skin cell Induced neuron/endothelial
cell
ASCL1, BRN2, MYT1l/ETV,
FOXC2, FLI1
DNA via nano-transfection Mouse+ injury-induced
ischaemia
Gallego-Perez et al. [38]
Muscle stem cell Stem cell OCT4, SOX2, KLF4, cMYC Inducible transgenic DNA Mouse+ injury induced
senescence
Chiche et al. [18]
Hepatic fibroblast Hepatocyte HNF1A, HNF4A, FOXA3,
GATA4
DNA via AAV delivery Mouse+ liver fibrosis Song et al. [22]
Hepatoma cell Hepatocyte-like cell HNF1A, HNF4A, FOXA3 DNA via AAV delivery Mouse+hepatocellular
carcinoma
Cheng et al. [23]
Neuroblast Myelinating oligodendrocyte OLIG2, SOX10 DNA electro-poration Mouse+ induced
demyelination
Waly et al. [29]
Microglia Induced neuron NeuroD1 DNA via LV delivery Mouse Matsuda et al. [31]
Neuron Binucleate neuronal
heterokaryon
Fusion with bone-marrow
cells (BMCs)
BMC trans-plantation Mouse+Friedreich’s Ataxia Kemp et al. [25]
Rod photo-receptor Cone-like cell Split dCas9-activator/
repressor
DNA via AAV delivery Mouse+ retinitis pigmentos Moreno et al. [44]
Müller glial cell Retinal neuron ASCL1, TSA Inducible transgenic DNA Mouse+NMDA-induced
neuronal injury
Jorstad et al. [27]
Müller glial cell Rod photoreceptor neuron b-Catenin; OTX2, CRX, NRL DNA via AAV delivery Mouse+congenital blindness Yao et al. [28]
Müller glial cell Amacrine neuron via
reprogrammed hybrid
Fusion with bone-marrow
cells (BMCs)
Intravitreal injection of NMDA Mouse+NMDA-induced
neuronal injury
Pesaresi et al. [26]
Undefined skeletal muscle
cell
Stem cell-like cell Transient OCT4, SOX2, KLF4,
cMYC
Inducible transgenic DNA Mouse+ surgical skeletal
muscle injury
de La´zaro et al. [35]
Undefined cardiac cell Cardiomyocyte-like cell GATA4, MEF2c, TBX5 DNA on gold nanoparticles Mouse+myocardial infarction Chang et al. [33]
Cardiac fibroblast Cardiomyocyte-like cell CRFVPTM drug cocktail Orally and intra-peritoneal inj. Mouse Huang et al. [34]
Cardiac fibroblast Cardiomyocyte-like cell GATA4, MEF2c, TBX5 Sendai virus vectors Mouse+myocardial infarction Miyamoto et al. [32]
Germ cell Neuron CHE-1; FACT depletion Inducible transgene C. elegans Kolundzic et al. [7]
Abbreviations. NMDA:N-methyl-D-aspartate; CRFVPTM: C – CHIR99021, R – RepSox, F– Forskolin, V – VPA, P – Parnate, T – TTNPB, M – Rolipram; TSA: histone deacetylase inhibitor Trichostatin-A;
AAV: adeno-associated viral; LV: lentiviral; ind.: induced.
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In vivo reprogramming Ofenbauer and Tursun 13cardiomyocytes in vivo, which, in contrast to TF-based
reprogramming, depends on injury-induced fibroblast
activation [34].
For transient OKSM induction in skeletal muscle, Wang
et al. used plasmids instead of viral vectors, as this
approach might be safer than using genome integrating
lentiviruses or retroviruses for future clinical applications
[40]. Taken together, these alternative delivery strategies
hold great promise for future clinical applications that rely
on in vivo reprogramming of patients’ endogenous cells to
repair and regenerate tissue.
CRISPR/dCas9-based synthetic TFs for in vivo
reprogramming
The genome-editing tool CRISPR/Cas9 is becoming
increasingly popular to support or induce reprogramming.
Wang et al. used CRISPR/Cas9 to knockout the MyoD
gene in mouse myoblasts, resulting in their transdiffer-
entiation to brown adipocytes [40]. Furthermore, a modi-
fied Cas9 that is deficient for its DNA cutting activity, but
still binds DNA (deactivated Cas9 or dCas9), can be fused
to transcription activators or repressors [41]. These
CRISPR/dCas9-TFs can simultaneously target several
genes, using different guide RNAs, to reprogram somatic
cells in vitro into neurons [42] or iPSCs [43] and rod cells
into cone cells in vivo [44]. Importantly, the application
of this technology for in vivo reprogramming requires the
large size of the dCas9 gene, which further increases upon
fusion to transcriptional modulators, to be taken into
account. Also, the need for guide RNAs, as well as
potential immunogenicity of the Cas9 protein, must be
considered [45]. Nevertheless, CRISPR/dCas9-TFs
might prove to be powerful tools to induce or enhance
in vivo reprogramming approaches.
Reprogramming inhibitory mechanisms
The efficiency of reprogramming is generally limited due
to cell fate safeguarding mechanisms, which act as barriers
for reprogramming [7,8]. We already mentioned the
necessity of a histone deacetylase inhibitor to reprogram
MGCs into neurons upon ectopic expression of Ascl1 in
mice which were older than 16 days [27]. Our current
knowledge of reprogramming barriers is continuing to
grow (reviewed in Refs. [46,47]), in part also due to
studying in vivo reprogramming in model organisms such
as the nematode C. elegans. It allows investigating repro-
gramming barriers in vivo due to genetic tractability, ease
of transgenesis and the feasibility of performing large-
scale genetic screens [7,8]. For instance, the histone
chaperones LIN-53 (RBBP4/CAF-1p48) and FACT
(facilitates chromatin transcription) were initially identi-
fied in C. elegans as cell fate reprogramming barriers. Their
mammalian counterparts were shown to block reprogram-
ming to iPSCs and transdifferentiation to neurons in mice
and human cells [7,47]. These examples demonstrate that
understanding cell fate protection in model organisms canwww.sciencedirect.com help to increase reprogramming efficiency of human cells
for future regenerative medicine applications (Table 1).
Concluding remarks and perspectives
Our current knowledge of fate-specifying TFs is derived
mainly from decades of classic developmental biology
research. In vitro studies taught us how to translate this
knowledge to reprogram cell fates, either back to a more
pluripotent state or to another differentiated fate – even
across germline layers. Importantly, recent studies
revealed that some findings cannot directly be translated
to an in vivo setting, largely due to specialized micro-
environments or required processes such as senescence.
While our overall understanding of inducing cellular
reprogramming is rapidly growing [48], we need to better
understand the global changes during these processes at
the molecular level. Besides chromatin and gene expres-
sion dynamics, also metabolic processes emerge as an
important layer of reprogramming checkpoints [49]. Nat-
ural transdifferentiation events provide an alternative
system to study how cell fate conversion is orchestrated
in a robust way. In C. elegans, the developmentally pro-
grammed transdifferentiation of a rectal epithelial cell to a
neuron has been studied in great detail and revealed key
insights into the interplay of TFs and different chromatin
regulators during transdifferentiation [50]. Another
recently discovered natural conversion event in C. elegans
is a sex-dependent glial cell to neuron conversion, which
happens only in sexually mature males [51]. Studying
naturally occurring in vivo reprogramming phenomena,
together with the application of single-cell transcriptome
analysis during different reprogramming events, will help
to dissect generalizable and specific molecular trajectories
of cell fate conversion. While such insights are critical to
enhance in vivo reprogramming, the emergence of orga-
noid technology might further help to investigate repro-
gramming in an in vivo like system, leading to enhanced
strategies for applying reprogrammed cells for tissue
replacement therapies in the future.
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